Indian Journal of Pathology and Microbiology
Home About us Instructions Submission Subscribe Advertise Contact e-Alerts Ahead Of Print Login 
Users Online: 8948
Print this page  Email this page Bookmark this page Small font sizeDefault font sizeIncrease font size
 
ORIGINAL ARTICLE
Ahead of Print

Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas


1 Department of Pathology, Faculty of Medicine, Bezmialem Vakıf University, Istanbul, Turkey
2 Ministry of Health, Cam Sakura City Hospital, Department of Pathology, Istanbul, Turkey
3 Department of General Surgery, Faculty of Medicine, Bezmialem Vakıf University, Istanbul, Turkey
4 Department of Medical Oncology, Faculty of Medicine, Bezmialem Vakıf University, Istanbul, Turkey
5 Department of Radiology, Faculty of Medicine, Bezmialem Vakıf University, Istanbul, Turkey
6 Ministry of Health, İstanbul Training and Research Hospital, Department of Radiology, Istanbul, Turkey

Correspondence Address:
Zuhal Gucin,
Bezmialem Vakif University Department of Pathology, Adnan Menderes Boulevard , P.C. 34093 Fatih/İstanbul
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijpm.ijpm_1274_21

BACKGROUND: In recent years, stem cells have been defined as the main cell population responsible for resistance to anticancer therapies. AIM: This study aims to investigate potential associations between the stem cell population and the degree of tumor regression in breast carcinomas treated with neoadjuvant therapy. SETTINGS AND DESIGN: The study included 92 patients with breast carcinoma who received neoadjuvant therapy. Tumor regression was defined based on Miller and Payne grading system. Patients with grade 1 or 2 regression on a 5-point scale were included in group 1 (n = 37), grade 3 regression in group 2 (n = 32), and grade 4 or 5 regression in group 3 (n = 23). MATERIALS AND METHODS: Immunohistochemical staining was performed on paraffin block sections of every case using CD44, CD24, CD29, CD133, ID4, and ALDH1 antibodies to detect stem cells. STATISTICAL ANALYSIS USED: IBM Statistical Package for the Social Sciences (SPSS), version 23.0 (IBM Corp., Armonk, NY, USA) software was used for statistical analyses, and a P value less than 0.05 was considered statistically significant. RESULTS: Histologically high-grade tumors are more common in the near-complete/complete response group (P = 0.004). HER2-positive tumors were more common in the complete/near-complete response group (P = 0.054). Tumor cells positive for stem cell markers CD44 and CD24 were more common in the poor response group (P = 0.027 and P = 0.001, respectively). CD29 expression was reduced in the posttreatment residual tumor tissue in the near-complete/complete response group. CONCLUSION: High CD44 and CD24 expression may be a predictor of poor response/nonresponse to neoadjuvant therapy in breast carcinomas.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Gucin Z
    -  Buyukpinarbasili N
    -  Gecer MO
    -  Ersoy YE
    -  Turk HM
    -  Yildiz S
    -  Aksoy DO
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed573    
    PDF Downloaded38    

Recommend this journal